Squarepoint’s Insys Therapeutics, Inc. INSY Stock Holding History

Squarepoint’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-60,513	Closed	-$212K	–	2585
2018 Q4	$212K	Buy	60,513 +48,674	+411%	+$338K	﹤0.01%	1663
2018 Q3	$119K	Buy	+11,839	New	+$94.4K	﹤0.01%	1865
2018 Q2	–	Sell	-10,521	Closed	-$64K	–	2213
2018 Q1	$64K	Buy	+10,521	New	+$86.9K	﹤0.01%	1603
2017 Q4	–	Sell	-16,119	Closed	-$143K	–	2462
2017 Q3	$143K	Buy	+16,119	New	+$166K	﹤0.01%	1463
2017 Q1	–	Sell	-29,433	Closed	-$271K	–	2108
2016 Q4	$271K	Buy	+29,433	New	+$333K	0.01%	1218
2016 Q3	–	Sell	-19,600	Closed	-$254K	–	1389
2016 Q2	$254K	Buy	+19,600	New	+$286K	0.02%	804
2016 Q1	–	Sell	-12,600	Closed	-$361K	–	1583
2015 Q4	$361K	Buy	+12,600	New	+$349K	0.04%	709
2015 Q1	–	Sell	-9,718	Closed	-$205K	–	511
2014 Q4	$205K	Buy	+9,718	New	+$192K	0.2%	173

Other funds holding INSY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Squarepoint's INSY Position: Q1 2019 in Review

Squarepoint sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 60,513 shares — an estimated $212K sold.

Squarepoint first reported a position in INSY in Q4 2014 and held it in 8 quarters. The position peaked at $361K in Q4 2015. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

Squarepoint reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Squarepoint sold 60,513 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $212K.
Squarepoint first reported a position in Insys Therapeutics, Inc. in Q4 2014 and held it in 8 quarters.
Squarepoint's Insys Therapeutics, Inc. position peaked at $361K in Q4 2015.
98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on Squarepoint's 13F filing for Q1 2019, filed 15 May 2019.